A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

PURPOSE: Bevacizumab is an antibody against vascular endothelial growth factor (VEGF); sunitinib is an inhibitor of VEGF and related receptors. The safety and maximum tolerated dose (MTD) of sunitinib plus bevacizumab was assessed in this phase I trial. EXPERIMENTAL DESIGN: Patients with advanced so...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Rini, Brian I., Garcia, Jorge A., Cooney, Matthew M., Elson, Paul, Tyler, Allison, Beatty, Kristi, Bokar, Joseph, Mekhail, Tarek, Bukowski, R.M., Budd, G. Thomas, Triozzi, Pierre, Borden, Ernest, Ivy, Percy, Chen, Helen X., Dolwati, Afshin, Dreicer, Robert
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2009
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2756318/
https://ncbi.nlm.nih.gov/pubmed/19773375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0717
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi